Mantle cell lymphoma (MCL) is a lymphoproliferative disorder comprising about 6-10% of all B cell lymphoma cases. Ibrutinib is an inhibitor of Bruton tyrosine kinase (BTK), a key component of early B-cell receptor (BCR) signalling pathways. Although treatment with ibrutinib has significantly improved the outcome of MCL patients, approximately onethird of the patients have primary drug resistance while others appear to develop acquired resistance. Understanding the molecular events leading to the primary and acquired resistance to ibrutinib is essential for achieving better outcomes in patients with MCL. In this review, we describe the biology of the BCR signalling pathway and summarize the landmark clinical trials that have led to the approval of ibrutinib. We review the molecular mechanisms underlying primary and acquired ibrutinib resistance as well as recent studies dealing with overcoming ibrutinib resistance.
Mantle cell lymphoma (MCL) is a lymphoproliferative disorder derived from a subset of naive pre-germinal centre cells localized in primary follicles or in the mantle region of secondary follicles. It is a rather rare disorder, comprising about 6-10% of all B cell lymphoma cases. The median age at diagnosis is 68 years and the disease is more prevalent in males than females, with a ratio of 4:1 (Morton et al, 2006; Zhou et al, 2008) .
Despite major advances in the treatment of newly diagnosed MCL patients, the median progression-free survival (PFS) is less than 2 years (Gibson et al, 2004) and the outcome of patients with relapsed or refractory (R/R) disease is still poor. Salvage treatment regimens include, among others, bendamustine plus rituximab; rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP); rituximab plus cytarabine and bendamustine (R-BAC); rituximab plus dexamethasone, cytarabine and cisplatin (R-DHAP); rituximab plus fludarabine, cyclophosphamide and mitoxantrone (R-FCM); and rituximab plus gemcitabine and oxaliplatin (R-GemOx). Four biological treatments have recently been added to this arsenal of treatments: bortezomib, lenalidomide, temsirolimus and ibrutinib .
Ibrutinib is a first-in-class, oral, irreversible inhibitor of Bruton tyrosin kinase (BTK) (Pan et al, 2007) , which is a 76 kD polypeptide with 659 amino acid residues that is expressed in most cells of the haematopoietic lineages, except for T cells and plasma cells (Smith et al, 1994) . It is a member of the Tec family and has a pleckstrin-homology (PH) domain and a proline-rich Tec homology (TH) domain which contains a zinc-finger motif that is important for optimal activity and protein stability (Hyvonen & Saraste, 1997; Bradshaw, 2010) . It also contains SRC-homology (SH) 2, SH3 and carboxyl kinase domains (Fig 1) . BTK is strongly expressed in MCL (Cinar et al, 2013) ; increased phosphorylation of BTK at Y223 was observed in primary MCL cells (Chang et al, 2013) .
BTK signalling pathway of the B-cell receptor
The signalling pathway of the B-cell receptor (BCR) is essential for B cell development and maturation. BTK has been implicated in the development, differentiation and activation of B cells through its role in the BCR signalling pathway, as described below and depicted in Fig 2. The BCR is non-covalently associated with a disulphide-linked Iga-Igb heterodimer (also named CD79A and CD79B). Upon antigen binding to the BCR, a SRC family tyrosine kinase, such as LYN, phosphorylates the Iga and Igb immune-receptor tyrosine-based activation motifs, thereby creating docking sites for spleen tyrosine kinase (SYK) (Rolli et al, 2002) . In parallel, LYN also phosphorylates tyrosine residues in the cytoplasmic tail of the BCR co-receptor, CD19, which allows the activation of phosphatidylinositol-3-kinase (PI3K) (O'Rourke et al, 1998) . Cytoplasmic B cell adapter protein (BCAP) can also recruit PI3K (Okada et al, 2000) . Active PI3K phosphorylates the plasma membrane lipid phosphatidylinositol 4,5-bisphosphate (PIP2) to generate phosphoinositide phosphatidylinositol-3, 4, 5-trisphosphate (PIP3), which is essential for BTK recruitment through its PH domain (Saito et al, 2001) . The interaction between PIP3 and the PH domain of BTK allows SYK and LYN to fully activate BTK by transphosphorylation at Y551 Rawlings et al, 1996) . Activated SYK also phosphorylates the B cell linker (BLNK) protein, which in turn associates with both BTK and phospholipase c2 (PLCG2) through their SH2 domains. BTK is then phosphorylated and activated by SYK, while PLCG2 is dually phosphorylated and activated by SYK and BTK (Weber et al, 2008) .
Downstream signals to BTK
The BTK downstream signalling pathways are summarized in Fig 2. Upon BTK activation, PLCG2 catalyses the hydrolysis of PIP2 to generate inositol triphosphate (IP3) and diacylglycerol (DAG). IP3 induces the release of calcium from intracellular stores and influx of extracellular calcium, thereby activating nuclear factor of activated T cells (NFAT) transcription factors via calmodulin (CAM). Calcium and DAG also activate protein kinase Cb (PRKCB), which in turn activates the RAS/RAF/MEK/ERK signalling module that promotes cell growth and proliferation (Hashimoto et al, 1998) . PRKCB also activates the nuclear factor kappa B (NFkB) pathway through a scaffold complex that includes caspase recruitment domain family member 11 (CARD11; also known as CARMA1 and BIMP3), -cell lymphoma/leukaemia 10 (BCL10) and mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) (Shinohara et al, 2007) . This complex (BCL10-CARD11-MALT1) mediates NFkB activation through the classical NFkB pathway in which the I kappa B kinase (IKK) complex (IKKa, IKKb, regulatory IKKc subunit) phosphorylates IKB for proteosomal degradation, leading to nuclear translocation of the heterodimeric NFkB transcription factors (Weber et al, 2008) .
In addition to its role in BCR signalling, BTK also plays a role in the signalling pathways of a wide variety of B cell molecules, including cytokine receptors [CD19, CD38, CD40 (Satterthwaite & Witte, 1996; Takesono et al, 2002) ], G protein-coupled receptors [e.g., the CXCR4 chemokine receptor (de Gorter et al, 2007) and tumour necrosis factor receptors and Toll-like receptors (TLRs)]. BTK can form complexes with endosomal major histocompatibility complex class II molecules, CD40 and myeloid differentiation primary response 88 (MYD88) (Liu et al, 2011) , promoting TLR signalling. TLR9-induced BTK activation can provoke excessive autoantibody production and autoimmunity (Kubo et al, 2009) .
In the absence of BTK, BCR signalling is insufficient to induce late transitional B cells to differentiate into mature peripheral B cells. BTK mutant cells are defective in their response to BCR signalling, resulting in impaired calcium mobilization, activation of mitogen-activated protein (MAP) kinases, cytoskeleton rearrangements and transcriptional activation (Anderson et al, 1996; Solvason et al, 1998) . This leads to altered development and defects in functional responses, including cellular proliferation, expression of activation markers, cytokine and antibody production, and responses to infectious diseases. Conversely, overexpression of BTK in B cells results in spontaneous formation of germinal centres, plasma cell proliferation, antinuclear autoantibody production, and a systemic lupus erythematosus (SLE)-like autoimmune disease. These changes are the result of hyper-responsive BCR signalling and increased NFkB activation, which could be reversed by treatment with ibrutinib (Kil et al, 2012) .
Ibrutinib treatment of MCL
Preclinical studies in MCL cell lines and xenograft models have initially shown that ibrutinib inhibits BTK phosphorylation in B cell lymphoma cell lines, thereby inhibiting cell growth and survival (Cinar et al, 2013) . Ibrutinib was approved for the treatment of R/R MCL based on a phase 2 open label multicentre international study, in which 115 patients received a daily dose of 560 mg ibrutinib until disease progression or significant adverse events. The median PFS was 13Á9 months. Overall response (OR) was achieved in 68% of patients [47% partial response (PR) and 21% complete response (CR)]. Response rate was similar among those who received prior bortezomib treatment and those who did not. The median response duration in all patients was 17Á5 months (Table I) (Wang et al, 2013b) . Based on this study, ibrutinib received accelerated US food and Drug Administration approval for MCL patients who failed at least one line of therapy and was authorized in the European Union for the treatment of adult patients with R/R MCL. Clinical evidence for ibrutinib resistance in MCL In the original registration study (Wang et al, 2013b) , primary resistance, i.e. lack of response at initial ibrutinib therapy, was observed in about 30% of patients. Sixty-five patients discontinued ibrutinib administration; 50 of them (76Á9%) due to disease progression which was associated with a high tumour proliferative state and poor clinical outcomes (Chiron et al, 2014) .
Since then, several clinical groups have analysed data on ibrutinib resistance in MCL (Table I ). The total number of patients reviewed was 539. Data were collected between 2011 Fig 2. BTK involvement in the B-cell receptor signalling pathway. BTK activates PLCG2, leading to increased intracellular calcium concentrations and resulting in NFAT, NFKB and ERK1/2 activation. BCAP, B cell adapter protein; BCL10, B Cell CLL/Lymphoma 10; BLNK, B-cell linker; BTK, bruton tyrosine kinase; CAM, calmodulin; CARD11, Caspase recruitment domain family member 11; CN, calcineurin; DAG, diacylglycerol; ERK1/ 2, extracellular signal-regulated kinase 1/2 [also termed MAPK3/MAPK1]'; IKK, Ikappa B kinase; IP3, inositol triphosphate; ITAM, immunoreceptor tyrosine-based activation motif; LYN, LYN proto-oncogene; Src family tyrosine kinase;MALT1, mucosa-associated lymphoid tissue lymphoma translocation protein 1; MEK1/2, mitogen-activated protein kinase kinase 1/2 [also termed MAP2K1/MAP2K2]; NFAT, nuclear factor of activated T cells; NFKB, Nuclear factor kappa B; PIP2, phosphatidylinositol 4,5-bisphosphate; PIP3, phosphoinositide phosphatidylinositol-3, 4, 5-trisphosphate; PLCG2, phospholipase c2; PRKCB, protein kinase Cb; RAF1, Raf-1 proto-oncogene, serine/threonine kinaseSYK, spleen tyrosine kinase and 2015. About half of the patients on ibrutinib discontinued therapy. Primary resistance ranged from 10Á2% to 35% and acquired resistance ranged between 17Á5% and 54% among all ibrutinib-treated patients. Cheah et al (2015) analysed subsequent therapies given following ibrutinib resistance in 31 patients who received salvage chemo-immunotherapy. The objective response rate (ORR) was 32% and the CR rate was 19%. Patients received a variety of subsequent salvage regimens (Table II) . The median overall survival (OS) was 8Á4 months, the 1-year OR was 22% [95% confidence interval (CI) 8-40] and the median duration of response was 6 months (Cheah et al, 2015) . Martin et al (2016) also analysed 73/104 patients who received subsequent therapy after ibrutinib treatment (Table II) . Only 5/61 (7%) evaluable patients achieved CR and 13/61 (19%) achieved PR. Median PFS following subsequent therapy was 1Á9 months (95% CI 1Á0-2Á6). OS was 2Á9 months. The median OS in patients who were not treated after ibrutinib was 0Á8 months. In those who received post-ibrutinib therapy, the median OS was 5Á8 months. The median OS for each subsequent regimen ranged between 3Á7 and 19Á2 months (Table II) . Multivariate analysis of OS, taking into account the MCL International Prognostic Index (MIPI) and the type of subsequent therapy, did not show statistically significant predictive factors, from the start of the post-ibrutinib therapy (Martin et al, 2016) . Epperla et al (2017) reported an ORR of 65%, a median duration of response of 17 months, and a median OS of 22 months. Post-ibrutinib therapy included a variety of regimens in this cohort (Table II) . The median OS after ibrutinib failure was only 2Á5 months (Epperla et al, 2017) . Dreyling et al (2016) reported a phase 3 randomized trial in 280 patients with R/R MCL comparing single agent ibrutinib to temsirolimus. Ibrutinib treatment resulted in a significant improvement in PFS. The median number of prior lines of therapy was two. Primary resistance was observed in 28% of patients in the ibrutinib arm (Table I) . Subsequent therapy was given to 32% in the ibrutinib group, the most common of which were rituximab (n = 21, 15%), bendamustine (n = 15, 11%) and cyclophosphamide (n = 12, 9%) in the ibrutinib group (Table II) and rituximab (n = 36, 26%), ibrutinib (n = 32, 23%), bendamustine (n = 22, 16%) and cyclophosphamide (n = 19, 13%) in the tempsirulimus group .
More recently, remarkable outcomes were reported when ibrutinib was tested in combination with rituximab . Fifty patients who had received prior rituximab, were given continuous daily ibrutinib (560 mg) with weekly rituximab (375 mg/m 2 ) for 4 weeks in cycle 1 and then on day 1 of every cycle for up to eight cycles, followed by 2 years of maintenance therapy. Median age was 67 years (range 45-86), and the median number of previous regimens was three (range 1-9). The ORR improved, from 68% (CR 21%) when used as a single agent to 88% (CR 44%) when combined with rituximab in R/R MCL patients . Additionally, the authors aimed to evaluate the association between the number of proliferating cells (Ki-67-positive) and treatment outcomes. In 37 patients with Ki-67 ˂50%, the proportion of patients achieving an objective response was 100% (95% CI 90Á5-100), with a CR in 20 patients (54%, 95% CI 36Á9-70Á5). The median duration of response, median PFS and median OS were not reached in this subgroup. Among the 12 patients with Ki-67 ≥ 50%, the proportion of patients who achieved an objective response was 50% (95% CI 21Á1-78Á9), with a CR in two patients (17%, 2Á1-48Á4). Of the nine patients who discontinued As shown above, ibrutinib treatment greatly improved the outcomes of R/R MCL patients with unprecedented high response rates. However, the high rate of evolving primary and acquired resistance to the drug is becoming a major clinical issue. Ibrutinib resistance is associated with low response rate to most subsequent therapies, with short duration of response and dismal OS. So far, no clinical predictors have been identified for response and survival following ibrutinib resistance. It seems that early ibrutinib administration (first line or second line) is associated with better outcome. Allogeneic haematopoietic stem cell transplantation or combinations of ibrutinib with other novel agents are potential preferable future therapies to overcome ibrutinib failure (O' et al, 2016; Miklos et al, 2017) .
Molecular mechanisms underlying acquired ibrutinib resistance
The first evidence for ibrutinib-acquired resistance was observed in serial biopsies of ibrutinib-treated MCL patients. Two patients who progressed on ibrutinib after achieving PR with duration of 14 and 30 months, respectively, had a cysteine to serine mutation at the BTK binding site of ibrutinib (BTK C481S ). This mutation attenuates the covalent binding affinity of ibrutinib, rendering it ineffective (Chiron et al, 2014) and affects BTK's downstream signalling pathways (Fig 2) . Importantly, these mutations were not identified prior to ibrutinib treatment. Martin et al (2016) also observed acquired BTK C481S mutation in two of 10 patients with relapsed MCL in a retrospective series. The mutation was identified 12Á1 and 12Á6 months after ibrutinib administration (Martin et al, 2016) . The same mutation was previously described in chronic lymphocytic leukaemia (CLL) patients who had acquired resistance to ibrutinib (Woyach et al, 2014 (Woyach et al, , 2017 . In addition, an acquired mutation in PLCG2 was also observed in CLL, but it was not reported in MCL (Woyach et al, 2017) (Table III) . Hamasy et al (2017) generated six possible amino acid substitutions for the cysteine 481 codon and performed functional analysis of BTK. They identified three potential ibrutinib resistance scenarios for cysteine 481 substitution: (i) serine substitution is catalytically active and therefore predominates among patients; (ii) threonine substitution is also catalytically active, but predicted to be rare because it requires replacements of two nucleotides; and (iii) BTK variants replaced with arginine, phenylalanine, tryptophan or Review tyrosine completely abolish BTK's catalytic activity. Such substitutions presumably need compensatory mutations to confer ibrutinib resistance and, as such, are probably very rare. Glycine and tryptophan variants have not yet been reported but probably also provide resistance (Hamasy et al, 2017) .
Molecular mechanisms underlying primary resistance to ibrutinib
Primary resistance to ibrutinib is caused by molecular mechanisms other than ineffective ibrutinib inhibition due to the BTK C481S mutation. Rather, it involves sustained distal BCR signalling such as activation of PIK3 and protein kinase B (AKT) pathway, activation of the classical and alternative NFkB pathways, and initiation of cell cycle progression (Table III and Fig 3) .
PIK3-AKT pathway activation
Chiron et al (2014) reported that 6 MCL patients with primary or early-acquired resistance to ibrutinib (i.e., on therapy for less than 5 months) had activated downstream kinases in the BCR signalling pathway, namely, PI3K and AKT (Chiron et al, 2014) . Although this report was based on a small number of patients, Ma et al (2014) supported these finding with similar results in MCL cell lines. In three cell lines (Jeko-1, Mino and Granta-519), ibrutinib decreased phosphorylated BTK levels, but only p-ERK or p-AKT inhibition correlated with the extent of cell death (Ma et al, 2014) .
Classical and Alternative NFkB pathway
NFkB signalling is an integral part of the BCR signalling pathway. Rahal et al (2014) revealed a novel pathogenic mechanism for primary ibrutinib resistance in MCL models: activation of the alternative NFkB pathway. Ibrutinib-sensitive MCL cell lines showed constitutive BCR signalling that activated the classical NFkB pathway via BTK. As shown in Fig 2, BCR-mediates NFkB activation through the classical NFkB pathway in which the IKK complex (IKKa, IKKb, regulatory IKKc subunit) phosphorylates IKB for proteosomal degradation, leading to nuclear translocation of the heterodimeric NFkB transcription factors, predominantly the nuclear factor kappa B subunit 1 (NFKB1)/RELA dimer (Davis et al, 2010; Lee et al, 2011) . In contrast, ibrutinib-resistant MCL cell lines depended on the alternative NFkB pathway rather than on the classical pathway (Table III, Fig 3) , mediated by BTK. Rahal et al (2014) used RNA sequencing and singlenucleotide polymorphism arrays to show somatic mutations in MCL cell lines including nonsense mutations in tumour necrosis factor receptor-associated factor 2 (TRAF2) and deletions in TRAF3. These genes are negative regulators of the alternative NFkB pathway. Mutations in these genes seem to lead to their loss of function and to stabilization of the MAP3K14 (also known as NIK) enzyme that promotes processing of p100 to nuclear factor kappa B subunit 2 (NFKB2), resulting in constitutive activation of the alternative NFkB pathway. Genomic profiling of 165 archived MCL tumour samples identified recurrent mutations in TRAF2, BIRC3 and MAP3K14 in approximately 17% of all MCL tumour tissues. Based on these findings, Rahal et al (2014) concluded that MCL pathogenesis depends on either the BCR-BTK-NFkB (classical) or MAP3K14-NFkB (alternative) pathways (Fig 3) . They predicted that patients without mutations in the alternative NFkB pathway would be sensitive to ibrutinib treatment while the latter group is unlikely to benefit from anti-BTK therapy. It remains to be determined whether mutations in the alternative NFkB pathway are associated with primary resistance in patients receiving ibrutinib. Based Genetic abnormalities activate signalling pathways that result in survival and proliferation of the deregulated cells. BTK, Bruton tyrosine kinase; CARD11, caspase recruitment domain family member 11; CLL, chronic lymphocytic leukaemia; DLBCL, diffused large B cell lymphoma; MAP3K14, mitogen-activated protein kinase kinase kinase 14 (also termed NIK); MCL, mantle cell lymphoma; MYD88, myeloid differentiation primary response 88; NFkB, nuclear factor kappa B; NR, not reported; PLCG2, phospholipase c2; TRAF2/3, tumour necrosis factor receptor-associated factor 2/3.
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on these results, such patients may respond to MAP3K14 inhibition, a promising option for future development of targeted therapy (Rahal et al, 2014) ; a preliminary analysis (Lenz et al, 2016) has confirmed these findings. Wu and colleagues conducted whole exome sequencing on 27 MCL samples from 13 patients at diagnosis and/or relapse (Wu et al, 2016a) . Eighteen genes were found to be recurrently mutated in these samples, including known (ATM, MEF2B and KMT2D) and novel (S1PR1 and CARD11) mutation targets. CARD11, a scaffold protein required for BCRinduced NFkB activation, was subsequently screened in 173 additional MCL samples. CARD11 mutations were observed in 5Á5% of these cases. When overexpressed in vitro, CARD11 mutants conferred resistance to ibrutinib and lenalidomide (an NFkB inhibitor), providing new insights for ibrutinib resistance in MCL and continuous activation of NFkB pathway, regardless of the presence of BTK inhibitors (Wu et al, 2016a) . Primary resistance to ibrutinib due to a mutation in CARD11 was first described in diffuse large B cell lymphoma (DLBCL) (Lenz et al, 2008; Compagno et al, 2009; Davis et al, 2010) (Table III, Fig 3) .
Cell cycle initiation/progression
One of the major genetic hallmarks of MCL is the t(11:14) (q13:q32) chromosomal translocation between the cyclin D1 gene (CCND1) located on chromosome 11 and the immunoglobulin heavy-chain locus (IGH) on chromosome 14. This translocation leads to increased CCND1 transcription and CCND1 protein expression (Raffeld & Jaffe, 1991; Williams et al, 1991) . CCND1 activates cyclin-dependent kinase (CDK) 4 and CDK6 that phosphorylate retinoblastoma protein (RB1), thereby activating the E2F transcription factor and leading to G1-S cell cycle progression (Sherr, Fig 3 . Molecular pathways involved in ibrutinib resistance in MCL. Mutations in genes involved in the BCR signalling pathway, chemokine (CXCR4) signalling, TLR signalling and CD40 signalling, all result in survival and proliferation of mantle cells. AKT, AKT serine/threonine kinase; BCL10, B-Cell chronic lymphocytic leukaemia/lymphoma 10; BCR, B-cell receptor; BTK, Bruton tyrosine kinase; CARD11, caspase recruitment domain family member 11; CCND1, cyclin D1; CDK, cyclin-dependent kinase; CIAP, cellular inhibitor of apoptosis; CXCR4, C-X-C motif chemokine receptor 4; IKK, Ikappa B kinase; IRAK, Interleukin 1 receptor-associated kinase; ITAM, immunoreceptor tyrosine-based activation motif; LYN, LYN proto-oncogene, Src family tyrosine kinase;MALT1, mucosa-associated lymphoid tissue lymphoma translocation protein 1; MAP3K14, mitogen-activated protein kinase kinase kinase 14 (also termed NIK); MYD88, Myeloid differentiation primary response 88; NFKB, Nuclear factor kappa B; NFKB2, Nuclear factor kappa B subunit 2; PI3K, phosphatidylinositol-3-kinase; PRKCB, protein kinase Cb; RB1, retinoblastoma 1; RELA, RELA proto-oncogene, NF-kB subunit; RELB, RELB proto-oncogene, NF-kB subunitSYK, spleen tyrosine kinase; TLR, toll-like receptor; TRAF, tumour necrosis factor receptor-associated factor. 1994) (Fig 3) . Increased CCND1 levels also occur due to genomic deletions or point mutations in the 3 0 -untranslated region, resulting in shorter and more stable transcripts (Wiestner et al, 2007; Deshpande et al, 2009) . Mohanty et al (2016) reported that single E36K, Y44D or C47S CCND1 mutations increased CCND1 protein levels through defective proteolysis, which promoted resistance to ibrutinib in MCL cell lines. Moreover, mutant CCND1 or forced expression of the wild type gene led to increased resistance of MCL cell lines to ibrutinib. The Y44D mutant sustained ibrutinib resistance at supra-physiological concentrations of 5-10 lmol/L. Furthermore, primary MCL tumours with CCND1 mutations also expressed stable CCND1 protein and were resistant to ibrutinib (Mohanty et al, 2016) (Table III, Fig 3) .
The effect of the microenvironment on ibrutinib resistance
Interactions within the tumour microenvironment also affect proliferation, survival and drug resistance signals in MCL cells (Kurtova et al, 2009; Burger & Ford, 2011; Medina et al, 2012; Zhang et al, 2012) . Tumour cells that are present in the bone marrow and lymphatic tissues of relapsed and highgrade MCL patients indicate disease progression (Salaverria et al, 2006; Weigert et al, 2009) . Chiron et al (2016) suggested that the tumour's microenvironment provides support for proliferation and drug resistance of MCL cells, highlighting a selective approach for targeting the lymphoma niche. They showed that lymphoidlike (L-40L) cells are lymphoma's natural immediate microenvironment promoting MCL cell growth and proliferation, preventing apoptosis, and increasing drug resistance (Chiron et al, 2016) .
In another study that compared gene expression profiles and signalling pathways activity in tumour samples collected from peripheral blood and lymph nodes, BCR and the classical NFkB were active in MCL cells within the lymph node microenvironment. The activity of BCR signalling directly correlated with increased tumour proliferation and identified a subset of patients with inferior survival, suggesting that activation of BCR signalling drives tumour proliferation and determines the clinical outcomes of patients with MCL. Furthermore, mutations identified in genes encoding components of the BCR and NFkB pathways may amplify the cellular response to BCR engagement and promote BTKindependent NFkB activation and ibrutinib resistance (Saba et al, 2016) .
Overexpression of the transcription factor SRY-BOX 11 (SOX11) in MCL has been associated with more aggressive behaviour and worse outcomes. Balsas et al (2017) suggested that SOX11 contributes to a more aggressive phenotype by promoting MCL homing and invasion and increasing CAM-DR by direct regulation of CXCR4 and FAK expression and FAK/PI3K/AKT pathway activation. Inhibition of this pathway may represent an efficient strategy to overcome stromalmediated chemo-refractoriness in aggressive MCL (Balsas et al, 2017) .
Thompson et al (EHA annual meeting 2017, Abstract #E1377) aimed to identify pathways responsible for ibrutinib resistance. To that end, the researchers generated an acquired resistance model from the parental REC-1 ibrutinib-sensitive cell line by treating the cells with escalating doses of ibrutinib for 12 months. BCR activation by IgM stimulation in this model led to downregulation of the transcription factor interferon regulatory factor 4 (IRF4) in the ibrutinib-sensitive cell line but not in the acquired resistance cell line. In vitro co-culturing of REC-1 and primary MCL cells with CD40L inhibited apoptosis, reduced proliferation and prevented IRF4 downregulation following treatment with a BTK inhibitor. The authors suggested that CD40L protects cells from the effect of BTK inhibition and could have an important role in drug resistance pathways within the microenvironment. Supporting results were recently published by Jayappa et al (2017) and are described below in the section relating to BCL2.
Overcoming ibrutinib resistance
The latest studies acknowledge that ibrutinib resistance is unlikely to be attenuated, unless various oncogenic pathways are targeted simultaneously (Table IV) .
Heat shock protein inhibition
Heat shock protein (HSP) is a chaperone protein that stabilizes newly translated proteins in order to prevent their ubiquitination and degradation. In neoplasia, HSP90 (also termed HSP90AA1) is recruited by malignant cells to prevent proteosomal degradation of oncoproteins, therefore its inhibition results in oncoprotein degradation. The specific inhibitor AUY922 fully depleted BTK and IKB in MCL cell lines (Jeko-1, REC-1, Maver-1, z-138 and Granta-519), leading to decreased activity of the classical and the alternative NFkB pathways, and affecting ibrutinib-resistant neoplasia. If AUY922 is also effective in clinical trials, it might help to overcome R/R MCL (Jacobson et al, 2016) .
BCL2
The anti-apoptotic protein BCL2 is upregulated in several B cell lymphomas, including CLL, follicular lymphoma (FL), Waldenstrom macroglobulinaemia, the activated B-cell (ABC) subtype of DLBCL and MCL. In MCL, BCL2 upregulation was associated with deregulation of CCND1 expression caused by its translocation (Touzeau et al, 2011) . Li et al (2016) focused on the BCL2 anti-apoptotic pathway. BCL2 protein can be targeted for proteosomal degradation by the E3 ubiquitin ligase FBXO10. Immunohistochemical analysis of BCL2 and FBXO10 in MCL tumour tissues from 62 patients showed that BCL2 expression positively correlated with BTK expression. Increased levels of BCL2 were observed due to a defect in protein degradation because of reduced FBXO10 expression, as well as because of transcriptional upregulation through the BTK-mediated classical NFkB activation. RNA sequencing analysis confirmed that a set of anti-apoptotic genes (e.g. BCL2, BCL2L1 and DAD1) was downregulated by BTK short hairpin RNA. The downregulated genes also included those that are critical for B cell growth and proliferation, such as BCL6, MYC, PIK3CA and TNFRSF13C. The specific BCL2 inhibitor, , has demonstrated synergy with ibrutinib in inhibiting the growth of both ibrutinib-sensitive and -resistant cancer cells in vitro and in vivo (Axelrod et al, 2014; Chiron et al, 2015) . These results suggest co-targeting of BTK and BCL2 as a new therapeutic strategy for MCL, especially for patients with primary resistance to ibrutinib. Clinical trials assessing the safety and efficacy of ibrutinib + venetoclax in MCL (for example, NCT02419560 and NCT02471391) are ongoing. However, analysis of primary samples from patients with MCL and CLL revealed unexpected heterogeneous de novo resistance to this combination (Jayappa et al, 2017) ; the microenvironmental agonists IL10, CD40L and most potently, CpG-oligodeoxynucleotides -a surrogate for unmethylated DNA and a specific agonist for TLR9 signalling -generated resistance to ibrutinib + venetoclax. Samples incubated with these agonists promoted NFkB activation, especially activation of the alternative pathway, leading to enhanced expression of the anti-apoptotic proteins MCL1, BCL2L1 and survivin and decreasing BCL2 dependence. Conversely, inhibition of NFkB signalling blocked overexpression of these anti-apoptotic proteins and overcame resistance. Inhibitors of MCL1, BCL2L1 or survivin also overcame this resistance, showing a synergistic benefit with ibrutinib + venetoclax. Davids et al (2017) recently published a Phase I First-inHuman study of venetoclax in patients with R/R non-Hodgkin lymphoma. The analysis included 106 patients (of which 28 had MCL, however none had received ibrutinib or lenalidomide, and five had received prior bortezomib-based therapy). Venetoclax was administrated once daily until progressive disease or unacceptable toxicity at target doses ranging from 200 to 1,200 mg in dose-escalation and safety expansion cohorts.
The ORR of MCL patients was 75% whereas the estimated median PFS for the MCL population was 14 months. Selective targeting of BCL2 with venetoclax was well tolerated, and single-agent activity varied among non-Hodgkin lymphoma subtypes. The analysis determined that 1200 mg is the recommended single-agent dose for future studies in FL and DLBCL, with 800 mg being sufficient to consistently achieve durable response in MCL (Davids et al, 2017) .
MALT1 inhibition
MALT1 is a member of the BCM complex (Fig 1) that functions as a protease. CYLD cleavage may be used as a direct marker of MALT1 proteolytic activity (Staal et al, 2011) . Dai et al (2017) showed that MALT1 is constitutively active in a substantial number of MCL models, and that MCLs can be divided into two distinct subgroups based on their MALT1 activation status. To investigate whether inhibition of MALT1 can overcome BTK C481S -induced ibrutinib resistance, they expressed a BTK C481S cDNA or an empty vector in five MALT1-activated and two MALT1-inactive MCL cell lines and subsequently treated these cells with ibrutinib or with a MALT1 inhibitor. Introduction of the BTK C481S mutation rescued MALT1-activated cell lines from the toxic effect of ibrutinib. In contrast, in MALT1-inactive MCL cell lines, transduction of the BTK C481S mutant or an empty vector did not alter the cells' sensitivity to ibrutinib or to the MALT1 inhibitor. These data indicate that inhibition of MALT1 might be effective as a novel therapeutic option for patients failing ibrutinib therapy (Dai et al, 2017) .
IRAK4 antagonist
Pathological activation of TLR signalling results in autoimmune and inflammatory disease states. Activation of TLRs (except TLR3) recruits the signalling adaptor protein MYD88, which engages the interleukin-1 receptor-associated kinases IRAK4 and IRAK1, thereby activating the NFkB and type-1 IFN pathways to promote survival and expansion of autoantibody-producing B cells (Leadbetter et al, 2002; Lau et al, 2005) (Fig 3) . In DLBCL, Ngo et al (2011) showed that MYD88 mutant isoforms coordinate a stable signalling complex involving IRAK4 and IRAK1, in which IRAK4 phosphorylates IRAK1, causing constitutive NFkB activation, type I IFN signalling, and autocrine IL6/IL10 engagement of the JAK-STAT3 pathway. Inhibition of IRAK4 in ABC DLBCL cell lines harbouring the MYD88 mutant resulted in cell death due to down-modulation of survival signals, including NFkB and autocrine IL6/IL10 engagement of the JAK-STAT3 pathway. Furthermore, in xenograft models IRAK4 inhibition suppressed tumour growth both as a single agent and in combination with ibrutinib or the BCL2 inhibitor ABT-199 (Ngo et al, 2011) .
In 2013, Wang et al found that some MCL specimen express MYD88 mutations (Wang et al, 2013a) ; therefore, Ngo's findings from 2011 suggest that the IRAK4 antagonist may serve as a therapeutic target for diseases driven by aberrant MYD88 signalling (Table III, Fig 3) .
Combination therapy
de suggested that combination therapy might prevent ibrutinib resistance. Given that targeting BCRcontrolled integrin-mediated adhesion is of major relevance for the clinical efficacy of ibrutinib (de Rooij et al, 2012; Chang et al, 2013; Spaargaren et al, 2015) , and because BTK and PI3K regulate BCR signalling via different pathways , they investigated the effect of the PI3K inhibitor, idelalisib, either alone or in combination with ibrutinib, on this pathway. The authors showed that targeting more than one key component of the BCR pathway may overcome primary resistance or prevent acquired mono-therapy resistance. As it is highly unlikely that the cells will develop two mutations simultaneously, combination therapy may be beneficial for patients with primary resistance to ibrutinib. Chiron et al (2014) showed that co-treatment with the CDK inhibitor palbociclib and with a PI3K inhibitor can overcome BTK acquired mutation resistance, but not primary resistance. They suggested that inhibition of CDK4 stalls and prolongs the MCL cell cycle in the G1 phase. Prolonging G1 also inhibits NFkB activation; therefore, inhibiting the G1 phase with CDK4 and CDK6 inhibitors may assist blocking cell proliferation caused by ibrutinib resistance.
Non-coding RNAs
Another promising direction of understanding ibrutinib resistance is through the involvement of non-coding RNAs. Zhishuo et al (2013) showed that the transcription factors STAT3 and NFkB were constitutively active in MCL cells, whereas ibrutinib treatment downregulated these proteins. Phosphorylated STAT3 both regulates and is regulated by specific microRNAs (miRs). Inhibition of the oncogenic MIR155 (which is activated by BCR, and thus upregulated in B cell lymphomas) suppressed STAT3 and NFkB expression in MCL, thereby decreasing growth and migration of the cancer cells. The researchers further showed that ibrutinib downregulates MIR155. Therefore, studying the regulatory network of MIR155 might be insightful for understanding ibrutinib resistance.
Second-generation BTK inhibitors
Due the resistance mechanisms and off-target side effects of ibrutinib (Tucker & Rule, 2015) , more specific, second-generation BTK inhibitors have been developed, including, , ONO/GS-4059 and BGB-3111. Acalabrutinib was shown to be more potent and selective than ibrutinib in CLL patients . Importantly, offtarget kinases, such as epidermal growth factor receptor (EGFR), IL2-inducible T cell kinase (ITK) and TEC, were not inhibited by acalabrutinib, suggesting less untoward effects and toxicities Barf et al, 2017) . Additional patients and longer follow-up of the ongoing phase I/II clinical studies are needed to ascertain these potential advantages. To date, there is an ongoing open-label, phase 2 clinical trial of acalabrutinib in subjects with MCL (NCT02213926), and multiple trials on other haematological malignancies and solid tumours are underway [reviewed in (Wu et al, 2016c) ]. Acalabrutinib combinations with other agents, such as BCL2, PI3K and ALK inhibitors, will probably further increase the response rate and response duration of acalabrutinib in B cell malignancies Iragavarapu et al, 2015; Yang et al, 2015) . In the future, it would be interesting to explore whether acalabrutinib has different resistance mechanisms from those of ibrutinib.
Additional selective BTK inhibitors, such as ONO/GS-4059 (Walter et al, 2016) and BGB-3111a (Tam et al, 2015) , are under clinical development, thereby expanding the potential therapeutic options for B cell malignancies.
Conclusions
Since its approval, treatment with ibrutinib has significantly improved the outcome of MCL patients. Several novel second-generation BTK inhibitors that aim to be more specific than ibrutinib are currently in clinical trials and will probably further improve the therapeutic landscape (Wu et al, 2016b) . Understanding the molecular events leading to primary and acquired resistance to ibrutinib as well as to second-generation BTK inhibitors is essential for achieving better outcomes in MCL patients. Some patients might be spared from side effects of drugs that are not effective, while others could benefit from combination approaches that target the clone carrying the resistance-causing aberration. In this review, we summarized the mutant genes that are involved in the survival and proliferation mechanism of MCL tumour cells, showing that these mutations can lead to ibrutinib resistance. With the technical development of next generation sequencing and its consequent price reduction, we are certain that more associations between genes and ibrutinib resistance will be brought to light in the near future. Alongside gene mutations, other regulatory molecules, such as non-coding RNAs, may provide more insights to ibrutinib resistance mechanism, although this field has not yet been studied in MCL. Moreover, there are almost no predictors for treatment response and prognosis, and there is an unmet need for new reliable therapeutic markers for this population.
